Area of research
Reproductive Medicine · Obstetrics and Gynecology
Research interest
Research interests include Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, Occupational and environmental lung diseases, and Epigenetics and DNA Methylation.
FAT1 Is Differentially Expressed in Cancers Affecting the Serosal Cavities
The specificity of HEG1 as mesothelioma marker depends on the differential diagnosis.
Limited clinical utility of mutation-based circulating tumor DNA detection in pseudomyxoma peritonei
Cellular Plasticity in Malignant Transformation – Mesothelial cells
The Diagnostic Role of TFF1, TFF3, FOXA1, CA XII and TRPS1 in Serous Effusions.
Endometrial carcinomas with ambiguous histology often harbor TP53 mutations.
Grainyhead-Like 2 Expression Is Associated with Disease Progression, Chemoresistance and Poor Survival in Tubo-Ovarian High-Grade Serous Carcinoma
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Oncologic outcomes based on lymphovascular space invasion in node-negative FIGO 2009 stage I endometrioid endometrial adenocarcinoma: a multicenter retrospective cohort study
Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance.
Lymphovascular invasion and p16 expression are independent prognostic factors in stage I vulvar squamous cell carcinoma.
Correction to: Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma.
Molecular features for timely cancer diagnosis and treatment - tumors of the ovary, fallopian tube and endometrium.
Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations.
Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma.
External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification.
Molecular characteristics of low-grade serous carcinoma in effusions.
Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers
Exosome Secretion and Epithelial-Mesenchymal Transition in Ovarian Cancer Are Regulated by Phospholipase D
Exosome Secretion and Epithelial-Mesenchymal Transition in Ovarian Cancer Are Regulated by Phospholipase D.
Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies.
Endometrial Carcinoma: Molecular Cytogenetics and Transcriptomic Profile.
Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions.
Peptide vaccine targeting mutated <i>GNAS</i>: a potential novel treatment for pseudomyxoma peritonei.
Molecular testing on serous effusions.
The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma.
Primary uterine ectomesenchymoma harboring a DICER1 mutation: case report with molecular analysis.
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale.
Role of the Exosome Secretion Machinery in Ovarian Carcinoma: <i>In Vitro</i> and <i>In Vivo</i> Models
Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma